Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 장준 | * |
dc.date.accessioned | 2020-08-24T16:30:26Z | - |
dc.date.available | 2020-08-24T16:30:26Z | - |
dc.date.issued | 2019 | * |
dc.identifier.issn | 2287-3651 | * |
dc.identifier.other | OAK-27682 | * |
dc.identifier.uri | https://dspace.ewha.ac.kr/handle/2015.oak/255279 | - |
dc.description.abstract | Purpose: The influenza B virus diverges into two antigenically distinct lineages: B/Yamagata and B/Victoria. Influenza B is the dominant circulating virus during some influenza seasons, and recent data demonstrated that influenza A and B infection similarly cause severe clinical symptoms in hospitalized patients. Nucleoprotein (NP) is a good target for a universal influenza vaccine. This study investigated whether NP epitope variation within two lineages affects the dominant cytotoxic T lymphocyte (CTL) responses induced by vaccination and the resultant protective immunity. Materials and Methods: The NP of B/Yamagata/16/1988, the representative strain of the Yamagata lineage, includes a dominant CTL epitope, FSPIRITFL, while B/Shangdong/7/1997 from the Victoria lineage has one amino acid difference in this sequence, FSPIRVTFL. Two recombinant replication-deficient adenovirus (rAd)-vectored vaccines expressing either NP were prepared (rAd/B-NP(I) and rAd/B-NP(V), respectively) and administered to BALB/c mice intranasally. To examine the efficacy of vaccination, antibody responses, CTL responses, and morbidity/mortality after challenge were measured. Results: Both vaccines induce similar antibody and CD8 T-cell responses cross-reacting to both epitopes, and also confer cross-protection against both lineages regardless of amino acid difference. Conclusion: The rAd-vectored vaccine expressing the NP could be developed as universal influenza B vaccine which provides broader protection. © Korean Vaccine Society. | * |
dc.language | English | * |
dc.publisher | Korean Vaccine Society | * |
dc.subject | Cross protective immunity | * |
dc.subject | Cytotoxic T lymphocytes | * |
dc.subject | Epitope | * |
dc.subject | Influenza B virus | * |
dc.subject | Nucleoproteins | * |
dc.subject | Recombinant adenovirus | * |
dc.title | Nucleoprotein vaccine induces cross-protective cytotoxic T lymphocytes against both lineages of influenza B virus | * |
dc.type | Article | * |
dc.relation.issue | 1 | * |
dc.relation.volume | 8 | * |
dc.relation.index | SCOPUS | * |
dc.relation.index | KCI | * |
dc.relation.startpage | 54 | * |
dc.relation.lastpage | 63 | * |
dc.relation.journaltitle | Clinical and Experimental Vaccine Research | * |
dc.identifier.doi | 10.7774/cevr.2019.8.1.54 | * |
dc.identifier.scopusid | 2-s2.0-85062662190 | * |
dc.author.google | Lee S.-Y. | * |
dc.author.google | Kang J.-O. | * |
dc.author.google | Chang J. | * |
dc.contributor.scopusid | 장준(8735999100) | * |
dc.date.modifydate | 20231120165756 | * |